[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558162":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":32,"responsibleParty":130,"collaborators":11,"id":132,"slug":133,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":11,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":11,"enrollmentInfo":141,"targetDuration":11,"studyType":144,"phases":145,"briefSummary":136,"conditions":147,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ONO-4685","EXPERIMENTAL",null,[13],"Drug: ONO-4685",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.",[9],[20],{"name":21,"affiliation":5,"role":22},"Project Leader","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"North America Clinical Trial Support Desk","CONTACT","+18665877745(Toll-Free)","clinical_trial@ono-pharma.com",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":28},"International Clinical Trial Support Desk","+17162141777(Standard)",[33,46,51,59,63,71,80,84,92,100,109,118,122,126],{"facility":34,"status":35,"city":36,"state":37,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":11},"Aichi Cancer Center Hospital","RECRUITING","Nagoya","Aichi-ken","Japan","JP",{"type":41,"coordinates":42},"Point",[43,44],136.90641,35.18147,{"lat":44,"lon":43},{"facility":47,"status":35,"city":36,"state":37,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":48,"geoPoint":50,"contacts":11},"Nagoya University Hospital",{"type":41,"coordinates":49},[43,44],{"lat":44,"lon":43},{"facility":52,"status":35,"city":53,"state":53,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":54,"geoPoint":58,"contacts":11},"Akita University Hospital","Akita",{"type":41,"coordinates":55},[56,57],140.11667,39.71667,{"lat":57,"lon":56},{"facility":60,"status":35,"city":61,"state":62,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"National Cancer Center Hospital East","Kashiwa-shi","Chiba",{"facility":64,"status":35,"city":65,"state":65,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"Kyushu University Hospital","Fukuoka",{"type":41,"coordinates":67},[68,69],130.41667,33.6,{"lat":69,"lon":68},{"facility":72,"status":35,"city":73,"state":74,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":75,"geoPoint":79,"contacts":11},"Hokkaido University Hospital","Sapporo","Hokkaido",{"type":41,"coordinates":76},[77,78],141.35,43.06667,{"lat":78,"lon":77},{"facility":81,"status":35,"city":82,"state":83,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Tokai University Hospital","Isehara-shi","Kanagawa",{"facility":85,"status":35,"city":86,"state":86,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":87,"geoPoint":91,"contacts":11},"Kumamoto University Hospital","Kumamoto",{"type":41,"coordinates":88},[89,90],130.69181,32.80589,{"lat":90,"lon":89},{"facility":93,"status":35,"city":94,"state":94,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":95,"geoPoint":99,"contacts":11},"University Hospital Kyoto Prefectural University of Medicine","Kyoto",{"type":41,"coordinates":96},[97,98],135.75385,35.02107,{"lat":98,"lon":97},{"facility":101,"status":35,"city":102,"state":103,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":104,"geoPoint":108,"contacts":11},"Tohoku University Hospital","Sendai","Miyagi",{"type":41,"coordinates":105},[106,107],140.86667,38.26667,{"lat":107,"lon":106},{"facility":110,"status":35,"city":111,"state":112,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":113,"geoPoint":117,"contacts":11},"Okayama University Hospital","Okayama","Okayama-ken",{"type":41,"coordinates":114},[115,116],133.93333,34.65,{"lat":116,"lon":115},{"facility":119,"status":35,"city":120,"state":121,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Kindai University Hospital","Osaka Sayama-shi","Osaka",{"facility":123,"status":124,"city":125,"state":121,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Osaka University Hospital","NOT_YET_RECRUITING","Osaka-fu",{"facility":127,"status":35,"city":128,"state":129,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Cancer Institute Hospital of JFCR","Koto-ku","Tokyo",{"type":131,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100558162","phase-1-a-phase-i-study-to-investigate-the-tolerability-and-safety-of-ono-4685-given-as-monotherapy-in-t-cell-lymphoma-and-cllsll-100558162",false,"NCT06547528","A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL\u002FSLL","An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Inclusion Criteria:\n\n1. Patients with histopathologically confirmed diagnosis of one of the following subtypes as defined by the 2017 revision of the WHO classification of lymphoid malignancies:\n\n   Peripheral T-cell lymphoma(PTCL)\n   * Angioimmunoblastic T-cell lymphoma(AITL)\n   * Peripheral T-cell lymphoma, NOS(PTCL-NOS)\n   * Nodal peripheral T-cell lymphoma with TFH phenotype(nodal PTCL with TFH)\n   * Follicular T-cell lymphoma(FTCL) Cutaneous T-cell lymphoma(CTCL)\n   * Mycosis fungoides(MF)\n   * Sezary syndrome Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma(CLL\u002FSLL)\n2. Relapsed or refractory patients with tumors for which no established standard therapy is available, or refractory or intolerant to existing standard therapy judged by principal investigator or subinvestigator\n3. ECOG PS 0\\~2\n4. Life expectancy of at least 3 months\n\nExclusion Criteria:\n\n1. Patients with severe complications.\n2. Patients with multiple cancers.","ALL","18 Years",{"count":142,"type":143},108,"ESTIMATED","INTERVENTIONAL",[146],"PHASE1",[148],"Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","2025-06-01",{"date":151,"type":152},"2025-06-03","ACTUAL",{"date":154,"type":152},"2023-10-01",{"date":156,"type":143},"2029-04-30",{"name":5,"class":6},14]